arrow
R

Reinhard Dummer

University Hospital Zurich
H指数:152
被引数:12.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Value of Adjuvant Radiotherapy in the Treatment of Melanoma: A Multi-Center Analysis

辅助放射治疗在黑色素瘤治疗中的价值:一项多中心分析

Cancers
IF4.4
2026-09-090
OA
TPRG-04 ETOP 19-21 USZ-STRIKE: IMMUNOTHERAPY OR TARGETED THERAPY WITH OR WITHOUT STEREOTACTIC RADIOSURGERY FOR PATIENTS WITH BRAIN METASTASES FROM MELANOMA OR NON-SMALL CELL LUNG CANCER

TPRG-04 ETOP 19-21 USZ-STRIKE:针对黑色素瘤或非小细胞肺癌脑转移患者的免疫治疗或靶向治疗,联合或不联合立体定向放射外科

2026-08-070
OA
An anti-PMEL antibody−drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

在GNAQ/GNA11突变型黑色素瘤中具有Gq/11抑制剂载荷的抗PMEL抗体−药物偶联物:一项1期临床试验

2026-07-130
OA
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026

欧洲共识性多学科指南:侵袭性皮肤鳞状细胞癌。第一部分:诊断与预防 - 2026年更新

2026-05-070
OAAI
Translating ctDNA into cutaneous melanoma care: an international expert survey

将ctDNA应用于皮肤黑色素瘤护理:一项国际专家调查

2026-03-190
PRE
Targeting the tumor cell-intrinsic ITGB2 axis inhibits melanoma progression

靶向肿瘤细胞内源性ITGB2轴抑制黑色素瘤进展

2025-12-180
OAAI
Combination of the Novel RAF Dimer Inhibitor Brimarafenib With the MEK Inhibitor Mirdametinib Is Effective Against NRAS Mutant Melanoma

新型RAF二聚体抑制剂Brimarafenib与MEK抑制剂Mirdametinib联用对NRAS突变型黑色素瘤有效

2025-11-010
OAAI
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

辅助性尼沃鲁单抗和雷拉利单抗在III/IV期黑色素瘤中的应用:随机III期RELATIVITY-098试验

2025-10-180
OAAI
Publisher Correction: Feasibility of multiomics tumor profiling for guiding treatment of melanoma

出版者更正:多组学肿瘤分析在指导黑色素瘤治疗中的可行性

2025-08-010
OAAI
Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

将PD-1切换为BRAF + MEK抑制可改善接受第二疗程辅助黑色素瘤治疗患者的无复发生存期

2025-05-070
OA